Argot Partners

Argot Partners company information, Employees & Contact Information

Explore related pages

Related company profiles:

Argot Partners, a Danforth Company, is a strategic communications firm that provides a specific skillset and depth of knowledge in life sciences to help you deliver the right messages to the right audiences in ways that can positively impact the outcome of your business. We bring together communications counselors from a diverse set of backgrounds, including experience ranging from in-house biotherapeutics and agency roles, to Wall Street, expert networks and the scientific or medical field. We offer a broad suite of services to clients across all stages of their corporate evolution, from preclinical to commercial, in a number of industries within the life sciences, including therapeutics, bioeconomy and medtech. Our Practice Areas: • Corporate & Financial Communications • Investor Relations • Initial Public Offerings • Merged Media • Key Outcome, Partnership & Special Situation Communications • Creative Services • Market Research • Patient Recruitment for Clinical Trials • Commercial Readiness & Launch • Strategic & Operational Business Support from Danforth Advisors Through our affiliation with Danforth Advisors, Argot Partners can integrate with cross-functional specialists and services exclusively for life science companies, applying deep sector expertise, institutional knowledge and connections to support life science innovators across the entire corporate life cycle. We collaborate with our extended team at BW Health Group, a Danforth Company, to help clients with market research, patient recruitment for clinical trials and commercial readiness and launch. Argot Partners was founded in 2007 and is headquartered in New York, with offices in Boston and a footprint in other key US markets and London. In 2022 Argot became part of Danforth Advisors. To schedule an initial consultation, email: info@argotpartners.com.
Looking for a particular Argot Partners employee's phone or email?

Argot Partners Questions

News

FORE Biotherapeutics to Participate in Upcoming Investor Conferences - Business Wire

FORE Biotherapeutics to Participate in Upcoming Investor Conferences Business Wire

Tract Bio Announces Publication in Gastroenterology Revealing Potential Therapeutic Targets in the Evolution of Esophageal Adenocarcinoma Identified Using stemECHO™ Cloning Platform - PR Newswire

Tract Bio Announces Publication in Gastroenterology Revealing Potential Therapeutic Targets in the Evolution of Esophageal Adenocarcinoma Identified Using stemECHO™ Cloning Platform PR Newswire

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call - 富途牛牛

Alector to Host Second Quarter and Mid-Year 2025 Earnings Conference Call 富途牛牛

FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium - Business Wire

FORE Biotherapeutics to Participate in the Raymond James Private Biotech Symposium Business Wire

Danforth Advisors Acquires Argot Partners, Adding Strategic Communications to Range of Integrated Business Support Services for Life Science Companies - Yahoo Finance

Danforth Advisors Acquires Argot Partners, Adding Strategic Communications to Range of Integrated Business Support Services for Life Science Companies Yahoo Finance

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index EyePoint Pharmaceuticals

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs - GlobeNewswire

Alector to Host Virtual Research and Development Event Highlighting PGRN Franchise and Brain Carrier Programs GlobeNewswire

Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update - Quiver Quantitative

Alector, Inc. to Host Conference Call for Q2 2025 Results and Mid-Year Business Update Quiver Quantitative

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists EyePoint Pharmaceuticals

Abcuro Announces Participation in Upcoming Investor Conferences - Business Wire

Abcuro Announces Participation in Upcoming Investor Conferences Business Wire

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality EyePoint Pharmaceuticals

Cartesian Therapeutics Announces New Employment Inducement Grants - Business Wire

Cartesian Therapeutics Announces New Employment Inducement Grants Business Wire

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS) - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS) EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors EyePoint Pharmaceuticals

Innoviva to Participate in Upcoming Investor Conferences - Business Wire

Innoviva to Participate in Upcoming Investor Conferences Business Wire

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China Region EyePoint Pharmaceuticals

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Alector to Participate in Upcoming Healthcare Conferences - GlobeNewswire

Alector to Participate in Upcoming Healthcare Conferences GlobeNewswire

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Strengthens Executive Leadership Team with Key Hires EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors EyePoint Pharmaceuticals

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting - Business Wire

ReNAgade Therapeutics Announces Presentations at the ASGCT 27th Annual Meeting Business Wire

Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire

Cartesian Therapeutics Announces New Employment Inducement Grants GlobeNewswire

Neurodegenerative Disease Pioneer Alector Sets Major Investor Conference Schedule for September 2025 - Stock Titan

Neurodegenerative Disease Pioneer Alector Sets Major Investor Conference Schedule for September 2025 Stock Titan

Mariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial Officer - Business Wire

Mariana Oncology Expands Management Team, Appoints Linda Bain Chief Operating Officer and Chief Financial Officer Business Wire

EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility EyePoint Pharmaceuticals

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion - Business Wire

Deciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 Billion Business Wire

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) - Business Wire

European Medicines Agency Accepts Deciphera’s Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Business Wire

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg EyePoint Pharmaceuticals

Mariana Oncology Announces $175 Million Series B Financing - Business Wire

Mariana Oncology Announces $175 Million Series B Financing Business Wire

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer - Business Wire

Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer Business Wire

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium - Business Wire

Alterome Therapeutics to Present Preclinical Data for its KRAS Selective Inhibitor ALTA3263 at the 2024 ENA Symposium Business Wire

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences - FinancialContent

Deciphera Pharmaceuticals to Participate in Upcoming Investor Conferences FinancialContent

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg - EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg EyePoint Pharmaceuticals

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference - GlobeNewswire

Baudax Bio to Present at the 24th Annual H.C. Wainwright Healthcare Conference GlobeNewswire

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim - Business Wire

Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim Business Wire

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies - Business Wire

Alterome Therapeutics Extends Series A to Nearly $100 Million to Advance Alteration-Specific Cancer Therapies Business Wire

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - FinancialContent

Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference FinancialContent

, the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection - MultiVu

, the First Oral Prescription Tablet Proven to Normalize B12 Levels Without the Need for an Injection MultiVu

Top Argot Partners Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant